HCC Clinical Trials

197 recruitingLast updated: June 18, 2026

There are 197 actively recruiting hcc clinical trials across 34 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1. Top locations include Shanghai, Shanghai Municipality, China, Guangzhou, Guangdong, China, Hangzhou, Zhejiang, China. Updated daily from ClinicalTrials.gov.


HCC Trials at a Glance

197 actively recruiting trials for hcc are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Phase 2 with 76 trials, with the heaviest enrollment activity in Shanghai, Guangzhou, and Hangzhou. Lead sponsors running hcc studies include Fudan University, IRCCS Azienda Ospedaliero-Universitaria di Bologna, and Chang Gung Memorial Hospital.

Treatments under study

About HCC Clinical Trials

Looking for clinical trials for HCC? There are currently 40 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 197 trials

Recruiting
Phase 1Phase 2

A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health30 enrolled21 locationsNCT07547553
Recruiting
Phase 1

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

Solid TumorsHepatocellular Carcinoma (HCC)Malignant Melanoma+1 more
Chiome Bioscience Inc.66 enrolled5 locationsNCT06636435
Recruiting

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

HCC - Hepatocellular CarcinomaCTTACE(Transcatheter Arterial Chemoembolization)
Zhongda Hospital121 enrolled1 locationNCT07351669
Recruiting
Phase 2

Y-90 Treatment Response Using Transarterial Radioembolization

Liver CancerHepatocellular CarcinomaPrimary Liver Cancer+3 more
Thomas Jefferson University30 enrolled1 locationNCT07145801
Recruiting

mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis

CirrhosisHepatocellular Carcinoma (HCC)Epigenomics+1 more
Central Hospital, Nancy, France400 enrolled1 locationNCT06778317
Recruiting

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

Liver surgeryHepatocellular Carcinoma (HCC)Adjuvant Chemoradiotherapy+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University11,000 enrolled1 locationNCT07417800
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerEsophageal CancerGastric Cancer+9 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 2

Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

Hepatocellular Carcinoma (HCC)
Shunda Du32 enrolled1 locationNCT07639138
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Hepatocellular Carcinoma (HCC)
City of Hope Medical Center600 enrolled1 locationNCT07265271
Recruiting
Not Applicable

Effect of the HCC Liver-Link Intervention

HCCRacial Disparities
Indiana University40 enrolled2 locationsNCT06728293
Recruiting

Liver Cancer Registry Platform

CholangiocarcinomaHepatocellular Carcinoma (HCC)
iOMEDICO AG1,000 enrolled1 locationNCT04510740
Recruiting
Phase 1

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Phase 2

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Hepato Cellular Carcinoma (HCC)
IRCCS Azienda Ospedaliero-Universitaria di Bologna15 enrolled1 locationNCT07276100
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb198 enrolled59 locationsNCT07291076
Recruiting
Not Applicable

Improving the Use of Immunotherapy to Treat Liver Cancer

Hepatocellular Carcinoma (HCC)
Universitaire Ziekenhuizen KU Leuven300 enrolled4 locationsNCT07623265
Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled33 locationsNCT05919264
Recruiting
Phase 2

Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

Hepatocellular Carcinoma (HCC)Portal Vein Tumor Thrombus
First Hospital of China Medical University38 enrolled1 locationNCT07483359
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 2

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy

Hepatocellular Carcinoma (HCC)
CHA University80 enrolled1 locationNCT07493668